secwatch.observer — SEC 8-K summary
======================================

Issuer:     AIM ImmunoTech Inc. (AIM)
CIK:        0000946644
Form:       8-K
Filed at:   2026-02-05T23:59:59+00:00
Accession:  0001493152-26-005208
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Positive interim Phase 2 data for Ampligen+Imfinzi in metastatic pancreatic cancer
--------------------------------------------------------------------------------

- 18 patients enrolled in DURIPANC Phase 2; combination well-tolerated with only two grade 3 immune-related AEs.
- Promising PFS and OS from Phase 1 continue in Phase 2; detailed data expected for publication later this year.
- Patients report high quality of life during treatment despite advanced PDAC.
- Immune profiling shows coordinated activation of innate and adaptive immune responses by Ampligen+durvalumab.
- AIM holds US patent for Ampligen+anti-PD-L1 combination to 2039; orphan drug designations in US and EU.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/946644/000149315226005208/0001493152-26-005208-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/946644/000149315226005208/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-005208

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer